MediWound Ltd. (MDWD)
MediWound Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Yavne, HM, IL. The stock last traded at $13.84, up 0.07% on the session, giving a market capitalisation of $177.8M. On trailing twelve-month figures it carries a trailing P/E of -8.65, a net margin of -170.1%. Its beta of 0.14 implies it has historically moved less than the broad market.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd. is most often compared with the following Healthcare names: